I mentioned this one yesterday for those interested in the contarian approach. ie biotechs have not exactly been doing well lately. This is the best time to buy of course. The question with biotechs given the long lead time and great risk is which one. It's a bit of a lottery in all honesty but I bought into ANX recently after looking closely at them. It will take a while but I believe they have potential.
Chuck
ANADIS LIMITED 2002-06-05 ASX-SIGNAL-G
HOMEX - Melbourne
+++++++++++++++++++++++++ Anadis scientists have demonstrated a new technique, tentatively titled "Bioshielding", for delivering delicate molecules (such as vaccines and pharmaceuticals) to the stomach wall. This technology is an important breakthrough achieved through our work with H pylori vaccines. The applications for this technology has benefits not only for Anadis' products currently in development but also for a wide range of existing products needing to be delivered to the gastrointestinal tract in an active state.
Preserving delicate molecules such as vaccine proteins to target the stomach wall has been impossible in the past because of the aggressive acid and digestive enzymes present which destroy any delicate molecule before it reaches its target. This breakthough means that direct drug treatment of the stomach lining is now possible. Many products that may have been shelved in the past by other drug developers because they were too delicate to survive the harsh environment around the stomach lining may now reach commercial reality.
Anadis has lodged a provisional patent covering the work done to date and is actively pursuing further research to expand other applications for this platform technology. As new applications for the technology are created Anadis will further define the existing patent or lodge further patents for this discovery.
C Graham MANAGING DIRECTOR & CEO
For further information Contact:
Conor Graham or Dr Grant Rawlin Telephone: 03 93586388 Facsimile: 03 93586399 Email: [email protected]
ANX Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held